Homburger advised UBS Switzerland on the issuance of fixed rate covered bonds in aggregate amount of € 1 bn, under the institute’s covered bond programme. The SIX-listed bonds yeald 2.783 % and will mature in 2030. In connection with
Tags :dx3
Homburger advised UBS Switzerland on the issuance of fixed rate covered bonds for an aggregate amount of CHF 510 million. The operation unfolded in two tranches – respectively of CHF 235 m at 0.560%, due 2030, and CHF 275 m at 0.935%,
Homburger advised Zürcher Kantonalbank (ZKB) on the issuance of EUR 500 m bail-in bonds, at 3.153%. BNP PARIBAS, Deutsche Bank, UBS Investment Bank and Zürcher Kantonalbank served as joint lead managers on the operation. The
DBAG Fund VIII, a private equity fund advised by Deutsche Beteiligungs (DBAG), has entered in an agreement to acquire MAIT Group from 3i Group. In connection with the deal, Bär & Karrer is representing
Borel & Barbey advised Siliance Capital throughout obtaining its licence from FINMA as a collective asset manager, in connection with its relocation from Luxembourg to Switzerland. The wealth management specialist – established in 2012 – moved from Hesperange
Advoro advised W. Rokitzky in joining the Danish InstallerGroup as part of its entry into the Swiss market. The parties Headquartered in Wallisellen, W. Rokitzky is a specialist in HVAC systems in the greater
Advoro and Walder Wyss advised Helvetica Property Investors in connection with the merger of Helvetica Swiss Opportunity Fund into Helvetica Swiss Commercial Fund. The context Pursuant to the consolidation, the HSO Fund was delisted from
Walder Wyss advised the Laveba cooperative group throughout renewing and simplifying its organisational structure. The context Headquartered in, the Laveba group is a cooperative trading and service company operating in the energy sector under the
Kellerhals Carrard advised Swiss deep tech company Jua.ai AG on its USD 11M Series A financing Round. The context Headquartered in Zurich, Jua.ai AG specialises on AI-based Earth simulation aimed at transforming
Vischer advised Mosanna Therapeutics in connection with its USD 80m Series A funding round. Headquartered in Basel, Switzerland, the clinical-stage biotech company, is working on a nighttime nasal spray to treat obstructive sleep apnea (OSA).
